Filing Details

Accession Number:
0001209191-20-049871
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-09-09 18:55:36
Reporting Period:
2020-09-04
Accepted Time:
2020-09-09 18:55:36
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
920465 La Jolla Pharmaceutical Co LJPC Biological Products, (No Disgnostic Substances) (2836) 330361285
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1178579 C Kevin Tang 4747 Executive Drive, Suite 210
San Diego CA 92121
Yes No Yes No
1191935 Tang Capital Partners Lp 4747 Executive Drive, Suite 210
San Diego CA 92121
No No Yes No
1232621 Tang Capital Management Llc 4747 Executive Drive, Suite 210
San Diego CA 92121
No No Yes No
1759910 S Michael Hearne 4747 Executive Drive, Suite 210
San Diego CA 92121
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-09-04 67,552 $3.82 9,194,673 No 4 P Indirect By LP
Common Stock Acquisiton 2020-09-08 84,152 $3.90 9,278,825 No 4 P Indirect By LP
Common Stock Acquisiton 2020-09-09 48,296 $4.01 9,327,121 No 4 P Indirect By LP
Common Stock Acquisiton 2020-09-09 78,369 $4.03 9,405,490 No 4 P Indirect By LP
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By LP
No 4 P Indirect By LP
No 4 P Indirect By LP
No 4 P Indirect By LP
Footnotes
  1. The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.66 to $3.97. TheReporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in footnotes 1 and 3 through 5 herein.
  2. The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP.
  3. The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.82 to $4.01.
  4. The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.91 to $4.10.
  5. The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.94 to $4.10.